Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males ; volume:24 ; number:1 ; day:14 ; month:3 ; year:2024 ; pages:1-9 ; date:12.2024
BMC endocrine disorders ; 24, Heft 1 (14.3.2024), 1-9, 12.2024
- Creator
-
Zilstorff, Dorte B.
Richter, Michael M.
Hannibal, Jens
Jørgensen, Henrik L.
Sennels, Henriette P.
Wewer Albrechtsen, Nicolai J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12902-024-01566-9
- URN
-
urn:nbn:de:101:1-2405162102121.426983464548
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zilstorff, Dorte B.
- Richter, Michael M.
- Hannibal, Jens
- Jørgensen, Henrik L.
- Sennels, Henriette P.
- Wewer Albrechtsen, Nicolai J.
- SpringerLink (Online service)
Other Objects (12)
Interaktion der GLP-1- und GIP-Rezeptoren
Vasodilator Effect of Glucagon: Receptorial Crosstalk Among Glucagon, GLP-1, and Receptor for Glucagon and GLP-1
Glucagon-like peptide 1 (GLP-1)
Einfluss von GIP (Gastric Inhibitory Polypeptide) und GLP-1 (Glucagon-like Peptide 7-36 Amide) auf die Insulinsekretion beim Hund
Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
GLP-1/glucagon receptor co-agonism for treatment of obesity
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism
Inflammatorische Regulation der Inkretinhormone GLP-1 und GIP und deren Relevanz für den Glukosemetabolismus
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Interaktion der GLP-1- und GIP-Rezeptoren
Vasodilator Effect of Glucagon: Receptorial Crosstalk Among Glucagon, GLP-1, and Receptor for Glucagon and GLP-1
Glucagon-like peptide 1 (GLP-1)
Einfluss von GIP (Gastric Inhibitory Polypeptide) und GLP-1 (Glucagon-like Peptide 7-36 Amide) auf die Insulinsekretion beim Hund
Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
GLP-1/glucagon receptor co-agonism for treatment of obesity
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism
Inflammatorische Regulation der Inkretinhormone GLP-1 und GIP und deren Relevanz für den Glukosemetabolismus
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Interaktion der GLP-1- und GIP-Rezeptoren
Vasodilator Effect of Glucagon: Receptorial Crosstalk Among Glucagon, GLP-1, and Receptor for Glucagon and GLP-1
Glucagon-like peptide 1 (GLP-1)
Einfluss von GIP (Gastric Inhibitory Polypeptide) und GLP-1 (Glucagon-like Peptide 7-36 Amide) auf die Insulinsekretion beim Hund
Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
GLP-1/glucagon receptor co-agonism for treatment of obesity
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism
Inflammatorische Regulation der Inkretinhormone GLP-1 und GIP und deren Relevanz für den Glukosemetabolismus